Main Article Content

Sohail Hussain
Faiza Nafees Khan
S. M. Qamrul Arfin
Muhammad Kamran
Sumbal Nasir Mahmood
Imtiaz Begum


Chronic HCV infection, end stage renal disease, hemodialysis, direct acting anti-viral therapy


 Chronic Hepatitis C virus infection is a matter of universal health concern, more so in a third world
country like Pakistan with significant disease prevalence. Patients with end stage renal disease
(ESRD) who are on maintenance hemodialysis are at an increased risk for developing this infection
due to various factors. The introduction of direct acting anti-viral (DAA) therapy for hepatitis C has
simplified treatment. However, challenges related to drug clearance and ribavirin induced anemia
persist in patients with ESRD. The aim of this study was to assess the efficacy and safety of DAA
therapy in chronic HCV patients requiring maintenance hemodialysis. 73 patients were analyzed,
who received a 12-week course of sofosbuvir and velpatasvir (without ribavirin). Sustained
virological response at week 12 (SVR-12) was achieved in 97.3% of the patients, equivalent to cure.
No treatment related side effects were noted in 40% of the patients, while remaining patients
experienced mild adverse effects not requiring treatment interruption or withdrawal. Hence, our
study proved that DAA therapy was both effective and safe in our patients with ESRD and
simultaneous chronic HCV infection.

Abstract 57 | pdf Downloads 31


1. Manns MP, Buti M, Gane ED, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat. Rev. Dis. Primers. 2017 Mar 2;3(1):1-9. doi:

2. Mooneyhan E, Qureshi H, Mahmood H, Tariq M, Maqbool NA, Anwar M, Aslam M, Azam F, Blach S, Khan AG, Hamid S. Hepatitis C prevalence and elimination planning in
Pakistan, a bottom‐up approach accounting for provincial variation. Viral Hepat J. 2023 Apr;30(4):345-54.

3. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Nov 1;65(11):186170. doi:

4. Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;4:939–47. doi:

5. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. American journal of nephrology. 2013 Nov 1;38(5):405-12.6. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al. PegIFNa/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62:24–30. doi:

6. Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin case. 2019;11:1270–81. doi:

7. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al.
PegIFNa/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated
mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62:24–30. doi:

8. Hu TH, Su WW, Yang CC, Yang CC, Kuo WH, Chen YY, Yeh YH, Chen SS, Tsao YY, Chen KM, Yan SL. Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. Am J Kidney Dis. 2021 Oct 1;78(4):511-9. doi:

9. Ministry of Health, Department of Health Surveillance, Department of STD, AIDS and Viral Hepatitis. Clinical protocol and therapeutic guidelines for hepatitis C and coinfections. Brasília: Ministry of Health; 2015.

10. European Association for the Study of the Liver. EASL Recommendations on Treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi:

11. Michels FB, AMARAL AC, CARVALHO-FILHO RJ, VIEIRA GD, SOUZA AL, Ferraz ML. Hepatitis C treatment of renal transplant and chronic kidney disease patients: efficacy and safety of direct-acting antiviral regimens containing sofosbuvir. Arq. Gastroenterol.2020 Feb 27;57:45-9. Doi:

12. Ryu JE, Song MJ, Kim SH, Kwon JH, Yoo SH, Nam SW, Nam HC, Kim HY, Kim CW, Yang H, Bae SH. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease. Korean J. Intern. Med. 2022 Aug 19;37(5):958-68. doi:

13. Mehmood Y, Ashraf MI, Mastoor K, Afzal A, Awan ZL. Effectiveness And Safety Of Sofosbuvir and Velpatasvir in Hemodialysis Patients Suffering With Hepatitis C Infection. Univ. Med. Dent. Coll. 2021 Feb 22;12(1):24-9.doi:

14. Khan RA, Ali A, Khan AY. Effectiveness of Sofosbuvir regime in Hepatitis C virus infection in haemodialysis Pakistani patients: Single Centre Study. Int. j. endorsing health sci. res. 2017;5(4):28-32.

15. Butt N, Abbasi A, Khan MA, Ali M, Mahesar GB, Haleem F, Manan A, Khan MA, Junejo AM. Treatment outcomes for patients undergoing hemodialysis with chronic hepatitis C on the sofosbuvir and daclatasvir regimen. Cureus. 2019 Sep 19;11(9). doi:

16. Cheema, S. U. R., Rehman, M. S., Hussain, G., Cheema, S. S., & Gilani, N. (2019). Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrol.20(1), 438.doi:

17. Jackson, W. E., & Everson, G. T. (2017). Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 11(6), 501–505. Doi:

18. Fabrizi, F., Cerutti, R., Dixit, V., & Ridruejo, E. (2021). Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with metaanalysis. Nefrologia, 41(5), 578–589.